London, UK, 25 Feb 2021: The o2h human health EIS Fund is pleased to announce an investment in Kuano, a London based company using quantum and AI to simulate  drug and virus interactions to identify drugs to shortcut the drug discovery process and improve the chances of success. 

Kuano has identified four attractive drug targets with huge commercial benefit to demonstrate their technology platform and if successful these could be licensed to big pharma. Simultaneously they will seek collaborative deals with pharma and biotech to leverage their technology platform to support their on-going innovations. 

o2h Ventures has a track record of nurturing and investing in some of the most innovative early stage biotech companies in the UK. Joining o2h Ventures in this investment round is Meltwind, Syndicate Room and Cambridge Angels. 

Sunil Shah, CEO at o2h Ventures said: “We are very pleased to back Kuano in this venture. Being able to more accurately understand and predict subtle changes around enzyme’s active sites could unlock faster opportunities to push inhibitors for difficult drug targets through discovery and development. Vid and Dave using their knowledge of quantum physics and Parminder with her previous big pharma and biotech drug discovery experience make a great team to both develop the platform and advance the drug assets from this. I am very much looking forward to joining the board and supporting this venture”.

Dr. Vid Stojevic, Co-Founder CEO of Kuano, said: “o2h Ventures have already been supportive over the last six months to develop our business model and also to identify high value drug targets. I am very excited to bring on a fund with the deep expertise and network that o2h Ventures can bring in the biotech space ”.

Editor’s Note:

About o2h Ventures:

The o2h human health EIS Fund is the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS qualifying seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information about o2h Ventures, please visit www.o2hventures.com

Media Contact:

Ajit Singh,

Marketing Manager,

ajit@o2h.com

About Kuano:

Kuano is an artificial intelligence company using quantum computing to create molecular design solutions that is headquartered in London, England and was founded in 2020 by Vid Stojevic, David Wright, Parminder Ruprah, and Jarryl D’Oyley.

Kuano focuses on developing enzyme inhibitors using artificial intelligence and quantum computing simulations for pharmaceutical, crop protection, and industrial chemistry applications. Properties of enzyme inhibitors being selected for by Kuano include enzyme binding transition states, enzyme transition state selectivity, and ability to maintain enzyme function regardless of possible mutations. Kuano manipulates enzyme properties to create enzyme inhibitors with more desirable dosage levels, toxicity levels, and resistance levels to mutations.

Examples of pilot projects worked on by Kuano include: designing transition state inhibitors for target enzymes, discovery requirements for resistance repair for specific compounds and classes of compounds, enzyme inhibition predictions, identifying distinct chemotypes, and expanding knowledge of a chemotype and the creation of a soft focus screening library.

For more information visit: https://www.kuano.ai/

Media Contact 

Vid Stojevic

Co-Founder and CEO at Kuano

vid.stojevic@kuano.ai

 

o2h-ventures